Drug Profile

NNC 03850434

Alternative Names: NNC 0385 0434; PCSK9i

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novo Nordisk
Class Antihyperlipidaemics
Mechanism of Action PCSK9 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Hypercholesterolaemia; Type 2 diabetes mellitus

Most Recent Events

04 May 2023 Novo Nordisk completes a phase I trial in Type 2 diabetes mellitus (In volunteers, In adults) in Canada and Germany (PO) (NCT05129891)
30 Sep 2022 Discontinued - Phase-I for Hypercholesterolaemia (In volunteers) in USA (PO) as of September 2022
30 Sep 2022 Discontinued - Phase-I for Hypercholesterolaemia (Treatment-experienced) in United Kingdom (SC) as of September 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com